Immatics’ treatment of Stage II and higher CM granted FDA orphan designation

Immatics (IMTX)’ treatment of Stage II and higher cutaneous melanoma, in human leukocyte antigen-A 02:01-positive patients, was granted FDA orphan designation, according to a post to the agency’s website.